1
|
Hochmair M, Terbuch A, Lang D, Trockenbacher C, Augustin F, Ghanim B, Maurer D, Taghizadeh H, Kamhuber C, Wurm R, Lindenmann J, Braz P, Bundalo T, Begic M, Bauer J, Reimann P, Müser N, Huemer F, Schlintl V, Bianconi D, Baumgartner B, Schenk P, Rauter M, Hötzenecker K. Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study. Cancers (Basel) 2024; 16:2586. [PMID: 39061224 PMCID: PMC11275022 DOI: 10.3390/cancers16142586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 07/05/2024] [Accepted: 07/17/2024] [Indexed: 07/28/2024] Open
Abstract
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018-December 2021 at 16 leading hospital institutions in Austria, excluding patients enrolled in clinical trials. In total, 319 patients were enrolled at a planned ~1:1:1 ratio across StI:II:III. Most tested biomarkers were programmed death ligand 1 (PD-L1; 58% expressing), Kirsten rat sarcoma virus (KRAS; 22% positive), and epidermal growth factor receptor (EGFR; 18% positive). Of 115/98/106 StI/II/III patients, 82%/85%/36% underwent surgery, followed by systemic therapy in 9%/45%/47% of those [mostly chemotherapy (ChT)]. Unresected treated StIII patients received ChT + radiotherapy [43%; followed by immune checkpoint inhibitors (ICIs) in 39% of those], ICI ± ChT (35%), and ChT-alone/radiotherapy-alone (22%). Treatment was initiated a median (interquartile range) of 24 (7-39) days after histological confirmation, and 55 (38-81) days after first medical visit. Based on exploratory analyses of all patients newly diagnosed with any stage NSCLC during 2018-2021 at 14 of the sites (N = 7846), 22%/10%/25%/43% had StI/II/III/IV. The total number was not significantly different between pre-COVID-19 (2018-2019) and study-specific COVID-19 (2020-2021) periods, while StI proportion increased (21% vs. 23%; p = 0.012). Small differences were noted in treatments. In conclusion, treatments were aligned with guideline recommendations at a time which preceded the era of ICIs and targeted therapies in the (neo)adjuvant setting.
Collapse
Affiliation(s)
- Maximilian Hochmair
- Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, 1210 Vienna, Austria
| | - Angelika Terbuch
- Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
| | - David Lang
- Department of Pulmonology, Johannes Kepler University Linz, Kepler University Hospital, 4829 Linz, Austria
| | | | - Florian Augustin
- Department of Visceral, Transplant and Thoracic Surgery, Medical University Innsbruck, 6020 Innsbruck, Austria
| | - Bahil Ghanim
- Department of General and Thoracic Surgery, University Hospital Krems, 3500 Krems an der Donau, Austria
| | - Dominik Maurer
- Department of Pulmonology, Ordensklinikum Elisabethinen Linz, 4020 Linz, Austria
| | - Hossein Taghizadeh
- Division of Oncology, Department of Internal Medicine I, University Hospital St. Pölten, 3100 St. Pölten, Austria
| | - Christoph Kamhuber
- Department of Oncology, Kardinal Schwarzenberg Klinikum, 5620 Schwarzach, Austria
| | - Robert Wurm
- Department of Pulmonology, Medical University Graz, 8036 Graz, Austria
| | - Jörg Lindenmann
- Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, 8036 Graz, Austria
| | - Petra Braz
- Department of Pulmonology, Landesklinikum Hochegg, 2840 Hochegg, Austria (P.S.)
| | - Tatjana Bundalo
- Department of Pulmonology, Landesklinikum Hochegg, 2840 Hochegg, Austria (P.S.)
| | - Merjem Begic
- Department of Thoracic Surgery, Medical University of Vienna, 8036 Vienna, Austria
| | - Johanna Bauer
- Department of Thoracic Surgery, Medical University of Vienna, 8036 Vienna, Austria
| | - Patrick Reimann
- Department of Oncology, Landeskrankenhaus Feldkirch, 6800 Feldkirch, Austria
| | - Nino Müser
- Department of Medicine II with Pneumology, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Ottakring, 1160 Vienna, Austria
| | - Florian Huemer
- Division of Pulmonology, Klinik Penzing, 1140 Vienna, Austria
| | - Verena Schlintl
- Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
| | | | | | - Peter Schenk
- Department of Pulmonology, Landesklinikum Hochegg, 2840 Hochegg, Austria (P.S.)
| | - Markus Rauter
- Department of Pulmonology, Klinikum Klagenfurt Am Woerthersee, 9020 Klagenfurt, Austria
| | - Konrad Hötzenecker
- Department of Thoracic Surgery, Medical University of Vienna, 8036 Vienna, Austria
| |
Collapse
|
2
|
Paz-Ares L, Mehta B, Wang Y, Obiozor C, Waterhouse D, de Langen AJ. Sotorasib in KRAS G12C mutated lung cancer - Authors' reply. Lancet 2024; 403:145-146. [PMID: 38218612 DOI: 10.1016/s0140-6736(23)02036-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 09/18/2023] [Indexed: 01/15/2024]
Affiliation(s)
- Luis Paz-Ares
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid 28041, Spain.
| | | | | | | | | | | |
Collapse
|